I
IDEAYA Biosciences, Inc. (IDYA)
NMS – Real vaqt narxi. Valyuta: USD
36.74
+0.45 (1.24%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
36.00
-0.74 (-2.01%)
Bozordan keyin: Jun 26, 2026, 6:30 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
36.74
+0.45 (1.24%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
36.00
-0.74 (-2.01%)
Bozordan keyin: Jun 26, 2026, 6:30 PM EDT
IDEAYA Biosciences, Inc., aniqlangan tibbiyot onkologiya kompaniyasi, Qo'shma Shtatlarda molekulyar diagnostika yordamida tanlangan bemorlar populyatsiyalari uchun maqsadli terapevtik vositalarni ishlab chiqadi. Kompaniya ko'z melanomasi, ko'z saratoni davolash uchun og'iz orqali qabul qilinadigan, kuchli va tanlab ta'sir etuvchi protein kinaza, C (PKC) ingibitori Darovasertibni taklif etadi va ko'plab klinik sinovlarda monoterapiya va krizotinib bilan birgalikda metastatik, neoadjuvant va adjuvant sozlamalar uchun baholanmoqda. Kompaniya shuningdek, SCLC va neyroendokrin karsinomalar davolash uchun DLL3 antitel dorilar kon'yunktura ingibitori IDE849; B7H3/PTK7 topo-I-payload bispecific BsADC IDE034; poliatribo-ribo glikohidrolaza ingibitori IDE161; BRCA yoki HRD bilan bog'liq boshqa mutatsiyalarga ega o'smalar davolash uchun 1-bosqich klinik sinovda bo'lgan Poly Theta Helicase ingibitori IDE705 (GSK101); MTAP-deleted o'smalar uchun MAT2A ingibitori IDE397; PRMT5 ingibitori IDE892; KAT6/7 ni tanlab ingibitsiya qiladi va ko'krak, o'pka, prostata va kolorektal saraton kasalliklari bo'lgan bemorlar uchun 1-bosqich dozani oshirish sinovida bo'lgan IDE574; Werner proteinining (WRN) gelykaz domenining og'iz orqali kichik molekula ingibitori va 1-bosqich klinik sinovda bo'lgan IDE275 ni taklif etadi. Bundan tashqari, kompaniya farmakologik ingibitsiyaga qaratilgan preklinik tadqiqot dasturlarini; sintetik lethality maqsad va biomarker kashfiyoti uchun DECIPHER dual CRISPR kutubxonasini; va uning dorilarni kashf etish platformasini yaxshilash uchun INQUIRE kimyoviy kutubxonasi va HARMONY mashinaviy o'rganish mexanizmlarini taklif etadi. Kompaniya GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, Manchester universiteti, Jiangsu Hengrui Pharmaceuticals Co., Ltd. va Les Laboratoires Servie bilan strategik ittifoqlarga ega. Shuningdek, u antitel-dorilar kon'yunkturasini baholash uchun AstraZeneca plc bilan klinik hamkorlik shartnomasiga ega; va MTAP-deleted, RAS-mutant oshqozon osti bezi o't yo'li adenokarsinomasi uchun RG6505, Roche'ning 1-bosqich pan-RAS ingibitori bilan birgalikda IDE892, IDEAYA'ning potentsial eng yaxshi-sinf 1-bosqich MTA-kooperativ PRMT5 ingibitorini baholash uchun Roche bilan klinik hamkorlikka ega. IDEAYA Biosciences, Inc. 2015 yilda tashkil etilgan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Dr. Joshua Bleharski Ph.D. | Chief Financial Officer |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Mr. Andres Ruiz Briseno CPA | Chief Accounting Officer |
| Mr. Daniel A. Simon | Chief Business Officer |
| Mr. Douglas B. Snyder | Chief Legal Officer |
| Mr. Mick O'Quigley | Senior Vice President of Medical Writing & Project Management |
| Mr. Stuart C. Dorman | Chief Commercial Officer |
| Ms. Francine Zelaya | Senior VP & Head of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-23 | 8-K | d39019d8k.htm |
| 2026-06-10 | 8-K | d110954d8k.htm |
| 2026-06-03 | 8-K | d53214d8k.htm |
| 2026-06-01 | 8-K | d138848d8k.htm |
| 2026-05-05 | S-3ASR | d83661ds3asr.htm |
| 2026-05-05 | 8-K | d949251d8k.htm |
| 2026-04-29 | DEF 14A | idya-20260429.htm |
| 2026-04-29 | ARS | ars_idya10k_20251231.pdf |
| 2026-04-13 | 8-K | d114952d8k.htm |
| 2026-04-09 | 8-K | d100891d8k.htm |